The Efficacy of Cardiac Contractility Modulation for Treating Patients with Heart Failure

Heart failure (HF) is still a leading cause of mortality and morbidity despite considerable advances in therapy. This study aimed to evaluate the efficacy of cardiac contractility modulation (CCM) for treating Chinese patients with HF.

This retrospective study included six HF patients who had New York Heart Association (NYHA) class II or III and received CCM implantation at the First Affiliated Hospital of Soochow University from May 2022 to May 2023. Assessments were conducted before and after 12 months of CCM treatment to evaluate the left ventricular ejection fraction (LVEF), the left ventricular end-diastolic dimension (LVEDD), the left atrium diameter (LAD), and cardiac function.

After the 12-month follow-up, all outcome measures showed improvement: the LVEF increased from (27 ± 4.73) % to (39.67 ± 7.06) %, the LVEDD decreased from (70.33 ± 1.97) mm to (64.83 ± 3.71) mm, and the LAD decreased from (52.83 ± 7.14) mm to (47.00 ± 7.48) mm. All patients reached NYHA functional class II.

The findings from this small study suggest that CCM therapy can enhance the cardiac functional status, improve LVEF, and reverse ventricular remodeling.